CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyTargeting DNA damage response in cancer therapyRoles of Chk1 in cell biology and cancer therapyAtaxin-3 promotes genome integrity by stabilizing Chk1.Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma.CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cellsTargeting the anaphase-promoting complex/cyclosome (APC/C)- bromodomain containing 7 (BRD7) pathway for human osteosarcoma.Getting Syk: spleen tyrosine kinase as a therapeutic target.Reduced expression of p21-activated protein kinase 1 correlates with poor histological differentiation in pancreatic cancer.Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer.Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer.Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinomaSUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancerConformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage.Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with ImatinibAlternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition.Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.Prognostic significance of BRCA1-associated protein 1 in colorectal cancer.Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma.Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma.Chk1 modulates the interaction between myosin phosphatase targeting protein 1 (MYPT1) and protein phosphatase 1cβ (PP1cβ).Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.ATR/CHK1 inhibitors and cancer therapy.DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells.Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.Suppression of Spleen Tyrosine Kinase (Syk) by Histone Deacetylation Promotes, Whereas BAY61-3606, a Synthetic Syk Inhibitor Abrogates Colonocyte Apoptosis by ERK Activation.Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.Prognostic value of spleen tyrosine kinase in human solid tumors.The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin
P2860
Q26745686-2BB5083D-D2F2-468B-9D7D-35E4EC64DAB9Q27023204-90FBB690-1B26-4984-B645-410E4794586AQ28289548-B51E9EA1-E35C-4E3F-94A7-52058DE3AD70Q33635896-D68B9EAF-F46F-41AF-A2B9-3199C1A12663Q33802043-57F8A517-34BC-4C0A-8383-9ACDA3DA9D47Q33815609-68834C0D-1359-4685-8DCF-6D25E6803268Q33917573-F5DA5FD6-0D7C-4908-ACBD-F8D5608FDE98Q33993750-FB46DC90-CEFA-4546-A8C0-E0F5C9C2847FQ34566032-4487FD4E-869B-4FE3-87D3-A7ECF056AA11Q34625171-2CFF22B6-9185-48A4-AB5E-C238F191464AQ34702116-1404EBFE-8169-4966-B22C-2D5F44E20F2BQ34786561-56CF7142-96F7-4C3F-BCCF-58E55F95D160Q35444029-54E7E102-AC2C-47C8-8B98-6D5E4BB07646Q36360734-CEF629C1-E0EF-4F16-8EBF-FFF616728012Q37065840-5DEF787C-0678-4E34-A109-60E071855E93Q37202328-98B1B097-B586-4B0F-A8FB-449903A70CA3Q37205238-60755E1F-DC55-4C7E-9470-BD0B3DC084F7Q37562328-0283A8C9-EDCB-4AAA-B423-73137B87E8A6Q37646934-31BB2F66-12F7-4287-AAC2-3CAE15E6ED8FQ38397568-10B7239B-DD22-4DAB-8174-D13B08716674Q38471666-3139E670-9FCB-4826-B323-75B5DAADFD07Q38974704-26A76BD6-0592-4869-A02F-9BDD1A22DD21Q38993024-1C03DC83-E922-4393-96AD-9E02722F6E1CQ39110553-B2B857BB-1957-40E7-838F-2F535404EE5BQ47269824-FBF5476F-D056-4B1F-B48F-B3D291473F92Q47365487-72E2D758-FCA2-4323-99F7-714F7E341CC3Q47622968-276D016E-98B1-410F-9F0F-BBAD904B15BEQ47634492-C2C570AF-20B3-448A-A0EB-5DBA2C404BFEQ48250645-4102521A-5860-449A-A482-4AEDC0A0506FQ51706615-A9E35478-852A-4635-B572-E5AF8CF3BAFCQ52656283-2A0EC083-1670-4004-B76E-1C6D3F5DBCC3Q52715849-A49C593E-61D4-4706-BB48-883E182DD8E0Q55345256-B40F4101-0231-44DA-B950-63BEFF0AEF88Q58694707-A6ABB867-36AA-4C83-8CE6-20978BF9077A
P2860
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@ast
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@en
type
label
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@ast
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@en
prefLabel
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@ast
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma
@en
P2093
Dongtai Chen
Guihua Chen
Jingxuan Pan
Kaishun Hu
Longjun Yang
Pinzhu Huang
Qiangui Bu
Ruhua Zhang
P2860
P304
P356
10.1172/JCI61380
P407
P577
2012-05-15T00:00:00Z